Authors
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
‘Huge Sellers’ Herald Changes in Japan Drug PricingThe latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?
Latest:
Eight Characteristics of Blockbuster TeamsThe secret sauce for creating blockbuster brands has always been - and always will be - consistently exceptional team execution. Andy Mehrotra offers the recipe.
Latest:
Emerging Pharma Leaders: Kaya Pai PanandikerVice President, Psychiatry Marketing, Lundbeck US
Latest:
New Challenge to IP InnovationSurvey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Latest:
Content Marketing’s Data Fail: Information Without Insight?A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.
Latest:
The Evolution of Regulatory OperationsMichael Gordon charts the evolution of regulatory operations and suggests how it can spearhead opportunities for innovation in pharma data.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
As Change Continues, Are You Digitally Fit For the Future?Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.
Latest:
Human Rights on the Pharma Risk Management AgendaMilana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Loss of Exclusivity: Strategies to Maximize Product ValueLoss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Latest:
Human Rights on the Pharma Risk Management AgendaMilana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
Latest:
PhRMA Dismayed by Global IPR ReportPharmaceutical Research and Manufacturers of America (PhRMA) International Vice-President Jay Taylor has expressed the organization’s concerns over the Office of the United States Trade Representative’s (USTR) 2013 Special 301 Report.
Latest:
Tufts Figures on Drug Development Spark DebateThe Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug.
Latest:
Indonesian Pharma Poised for Strong GrowthCPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.
Latest:
October 2016: Seizing the Commercial Opportunity from Big Data in Life SciencesLife sciences: the time is now for a comprehensive big data strategy.
Latest:
October 2016: Wisdom for the JourneyIn patient support programs, success-and your ROI-rests on making that vital connection between technology and the human touch.
Latest:
Biosimilars Gaining Traction as Regulator Confidence GrowsBiosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.
Latest:
Executive Pay and InnovationHow the need for biopharma innovation extends to questions around executive compensation.
Latest:
The State of Market Insights in PharmaIt's time to take advantage of a nascent technology embrace taking hold among market insights professionals.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
Latest:
Going to the EdgeHow a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.
